| P/E (FY) | — | Sales (TTM) | $79.2M |
| Earnings (TTM) | -$137.0M | ROE | — |
| Net Margin | −175.31% | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | −27.09% |
ADC Therapeutics SA provides an antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product, ZYNLONTA, is a CD19-directed ADC that received accelerated U.S. approval and conditional approvals in Europe and China for relapsed or refractory diffuse large B-cell lymphoma. The company is working to expand ZYNLONTA into additional markets and indolent lymphomas through Phase 3 and Phase 1b trials.
| Market Cap | $141.2M | Trading Days | 1554 |
| 52W High | 4.97 |
| 52W Low | 0.78 |
| % Off High | −77.67% |
| YTD | −68.56% | 1Y | −64.42% |
| 3Y | −13.28% | 5Y | −94.78% |
| Since incept. (ann.) | −41.12% |
Reportable 100%
| Ann. Volatility (1Y) | 94.51% | Ann. Volatility (3Y) | 114.39% |
| Sharpe (1Y) | −0.42 | Sharpe (3Y) | 0.56 |
| Max Drawdown (1Y) | −79.96% | Max Drawdown (3Y) | −81.51% |
| Beta (3Y, vs SPY) | 3.52 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| AARD | Aardvark Therapeutics, Inc. | $140.1M | — |
| CNTN | Canton Strategic Holdings, Inc. | $142.4M | — |
| MSLE | Satellos Bioscience Inc. | $146.2M | — |
| EQ | Equillium, Inc. | $146.7M | — |
| HURA | TuHURA Biosciences, Inc./NV | $135.6M | — |
| MIST | Milestone Pharmaceuticals Inc. | $133.2M | — |
| UNCY | Unicycive Therapeutics, Inc. | $131.9M | — |
| KRRO | Korro Bio, Inc. | $151.4M | — |
| GNLX | GENELUX Corp | $130.9M | — |
| PMN | ProMIS Neurosciences Inc. | $130.2M | — |
| DERM | Journey Medical Corp |
| $154.6M |
| — |
| NGEN | NERVGEN PHARMA CORP. | $128.2M | — |
